Research Papers:

Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy

Zhengguang Wang, Zhendong Liu and Song Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:31465-31477. https://doi.org/10.18632/oncotarget.16356

Metrics: PDF 2345 views  |   HTML 2877 views  |   ?  


Zhengguang Wang1, Zhendong Liu1, Song Wu1

1Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China

Correspondence to:

Song Wu, email: [email protected]

Keywords: osteosarcoma, long non-coding RNA, doxorubicin, resistance, autophagy

Received: October 27, 2016     Accepted: March 04, 2017     Published: March 18, 2017


Recently, several long non-coding RNAs (lncRNAs) have been implicated in osteosarcoma (OS). However, the regulatory roles of lncRNAs in chemotherapy resistance of OS still remain unclear. This study aimed to screen a novel lncRNA that contributes to chemotherapeutic resistance of OS, and to explore the underlying mechanisms. Our data showed that lncRNA CTA was markedly downregulated in OS tissues compared to their matched non-tumor tissues, and low expression of lncRNA CTA was significantly associated with the advanced clinical stage and tumor size. In addition, OS patients with low lncRNA CTA levels showed a worse prognosis when compared with those with high expression of lncRNA CTA. Furthermore, we report that lncRNA CTA has an inverse relationship with miR-210 expression in OS tissues. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR-210, while inhibit cell autophagy. On the other hand, lncRNA CTA was downregulated in DOX-resistant OS cells. Overexpression of lncRNA CTA reduced autophagy and subsequently overcame DOX resistance of OS in vitro and in vivo. Therefore, we demonstrate that lncRNA CTA is an essential regulator in DOX-induced OS cell apoptosis, and the lncRNA CTA-miR-210 axis plays an important role in reducing OS chemoresistance.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16356